Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Anlotinib combined with penpulimab and hepatic artery infusion chemotherapy (HAIC) in the first-line treatment of unresectable hepatocellular carcinoma.
Authors
Gong-Rang Chen
Yiyang Central Hospital, Yiyang, China
Gong-Rang Chen , Ting Zhong , Jian-Hua Cai , Juan Liang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr TPS579)
DOI
10.1200/JCO.2024.42.3_suppl.TPS579
Abstract #
TPS579
Poster Bd #
P8
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study.
First Author: Yongkang Xu
Poster
2022 ASCO Annual Meeting
Hepatic artery infusion chemotherapy (HAIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in BCLC stage c: A prospective, single-arm, phase II trial (TRIPLET study).
First Author: Yang-Kui Gu
Poster
2021 ASCO Annual Meeting
A phase II trial of lenvatinib plus toripalimab and hepatic arterial infusion chemotherapy as a first-line treatment for advanced hepatocellular carcinoma (LTHAIC study).
First Author: MinKe He
Poster
2023 ASCO Annual Meeting
Efficacy and safety of first-line treatments for patients with advanced hepatocellular carcinoma: A systematic review and network meta-analysis.
First Author: Danni Li